Ascendis Pharma A (ASND) Research & Development (2014 - 2026)
Ascendis Pharma A (ASND) posted Research & Development of -$69.1 million for Q1 2026, up 24.01% sequentially from -$91.0 million in Q4 2025, and up 24.12% YoY from -$55.7 million in Q1 2025.
Ascendis Pharma A (ASND) Research & Development (2014 - 2026) Analysis & Trends
Ascendis Pharma A has reported Research & Development for 13 years, with the latest figure at -$69.1 million in Q1 2026.
- Quarterly Research & Development rose 24.12% year-over-year to -$69.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$156.8 million (up 5.94% YoY) and the FY2025 annual result came in at $353.4 million, up 7.73% from the prior year.
- Research & Development rose to -$69.1 million in Q1 2026 per ASND's latest filing, from -$91.0 million in the prior quarter.
- Over five years, Research & Development peaked at $121.3 million in Q3 2023 and troughed at -$91.1 million in Q1 2025.
- A 5-year average of $35.3 million and a median of $89.9 million in 2024 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2025: Research & Development jumped 47.55% in 2022, then sank 218.63% in 2025.
- Over 5 years, Research & Development stood at $110.8 million in 2022, then declined by 11.76% to $97.8 million in 2023, then sank by 186.65% to -$84.7 million in 2024, then slipped by 7.36% to -$91.0 million in 2025, then rose by 24.01% to -$69.1 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered -$69.1 million, -$91.0 million, and -$78.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Ascendis Pharma A | 15.40 Bn | 14.73 Bn | 268.20 Mn | -69.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -69.13 Mn |
| Dec 31, 2025 | -90.97 Mn |
| Sep 30, 2025 | -78.19 Mn |
| Jun 30, 2025 | 81.49 Mn |
| Mar 31, 2025 | -91.10 Mn |
| Dec 31, 2024 | -84.73 Mn |
| Sep 30, 2024 | -80.77 Mn |
| Jun 30, 2024 | 89.90 Mn |
| Mar 31, 2024 | 76.79 Mn |
| Dec 31, 2023 | 97.78 Mn |
| Sep 30, 2023 | 121.31 Mn |
| Jun 30, 2023 | 114.36 Mn |
| Mar 31, 2023 | 113.90 Mn |
| Dec 31, 2022 | 110.82 Mn |
| Sep 30, 2022 | 98.24 Mn |
| Jun 30, 2022 | 96.44 Mn |
| Mar 31, 2022 | 93.37 Mn |
| Dec 31, 2021 | 75.10 Mn |
| Sep 30, 2021 | 69.30 Mn |
| Jun 30, 2021 | 100.32 Mn |